Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

Nicola Scichilone, Vincenzo Bellia, Pierluigi Paggiaro, Eugenio Sabato, Maria Teresa Busceti, Marchi, Segreti, Gianenrico Senna, Colombo, Ravazzi, Mario Cazzola, Marco Caminati, Manuela Latorre, Latorre, Palumbo, Paladini, Gundi Steinhilber, Maggi, Caterina Bucca, Adriano BerraGuarnieri, Scibilia, Letizia Vergura, Vergura, Macchia, Abbritti, Camiciottoli, Federica Novelli, Novelli, Vianello, Pierluigi Paggiaro, Cazzola, Pietro Schino, Alessandra Vultaggio, Anna Stanziola, Nicola Scichilone, Marco Bonavia, Gianna Camiciottoli, Alessandro Celi, Luigi Macchia, Baglioni, Andrea Matucci, Maria Filomena Caiaffa, Caiaffa, Almerigogna, Paola Rottoli, Girolamo Pelaia, Vincenzo Bellia, Rosario Maselli, Di Gioacchino, Calabrese, Piero Maestrelli, Gabriella Guarnieri, Andrea Vianello, Pastorello, Bargagli, Cagnazzo

Research output: Contribution to journalArticle

29 Citations (Scopus)


Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment.The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control.We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between poorly controlled and partially or well controlled asthmatics showed a statistically significant higher prevalence of some comorbidities in the first group, namely obesity, gastro-oesophageal reflux disease (GORD), aspirin intolerance and mental disorders (all p<0.001). Similarly, asthmatics with at least one exacerbation in the last year showed a significantly higher prevalence of obesity, chronic rhinosinusitis, nasal polyps, GORD, and aspirin intolerance (all p<0.05) than patients without exacerbations. When we selected patients without relevant comorbidities (upper airways disease, GORD, obesity, aspirin intolerance) and not currently smoking (. N=73), the percentage of well or partially controlled asthmatics was significantly higher than in patients with comorbidities (84.9% vs 71.1%, p=0.02); the rate of asthmatics without exacerbations in the last year was also higher (73.6% vs 51.1%, p=0.001).During omalizumab treatment, a high percentage of asthmatics obtain a good or partial control of asthma. Comorbidities are associated with the lack of asthma control and persistence of exacerbations.
Original languageEnglish
Pages (from-to)123-129
Number of pages7
Publication statusPublished - 2015

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Biochemistry, medical
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy'. Together they form a unique fingerprint.

  • Cite this

    Scichilone, N., Bellia, V., Paggiaro, P., Sabato, E., Busceti, M. T., Marchi, Segreti, Senna, G., Colombo, Ravazzi, Cazzola, M., Caminati, M., Latorre, M., Latorre, Palumbo, Paladini, Steinhilber, G., Maggi, Bucca, C., ... Cagnazzo (2015). Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. PULMONARY PHARMACOLOGY & THERAPEUTICS, 31, 123-129.